Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the 13 Biotech Stocks with Huge Upside Potential. JPMorgan has ...

JPMorgan lowered the firm’s price target on Regeneron (REGN) to $1,150 from $1,200 and keeps an Overweight rating on the shares. The firm updated estimates following the recent Eylea biosimilar ...

JPMorgan Chase & Co.‘s price target would suggest a potential ... TD Cowen reduced their price target on shares of Regeneron Pharmaceuticals from $1,230.00 to $1,030.00 and set a “buy ...

REGN has been the subject of several other reports. JPMorgan Chase & Co. lowered their price target on Regeneron Pharmaceuticals from $1,100.00 to $1,000.00 and set an “overweight” rating for ...

The latest price target for Regeneron Pharmaceuticals (NASDAQ:REGN) was reported by JP Morgan on June 9, 2025. The analyst firm set a price target for $800.00 expecting REGN to rise to within 12 ...

Oppenheimer lowered the firm’s price target on Regeneron (REGN) to $1,000 from $1,150 and keeps an Outperform rating on the shares.With the shares off about 30% since the surprising news of an ...

Wells Fargo lowered the firm’s price target on Regeneron (REGN) to $1,050 from $1,200 and keeps an Overweight rating on the shares. Given Regeneron’s failure to secure a stay against Amgen’s ...

Morgan Stanley analyst Terence Flynn lowered the firm’s price target on Regeneron (REGN) to $1,081 from $1,150 and keeps an Overweight rating on the shares. The firm adjusted its large cap ...